Khizer Bin Saad

M. Ali
M. Aizazullah
Adnan Rais Khan

79
76
32
03

GlaxoSmithKline often abbreviated to GSK, is a global

pharmaceutical, biologics, vaccines and consumer
healthcare company headquartered in London, United
Kingdom.

 science-led global healthcare company that researches

and develops a broad range of innovative products in
three primary areas of pharmaceuticals, vaccines and
consumer healthcare

26.5bn
2013 Group turnover (up 1% CER)

 GlaxoSmithKline plc is a public limited company incorporated

on 6th December 1999 under English law. Its shares are listed
on the London Stock Exchange and the New York Stock
Exchange.

On 27th December 2000 the company acquired Glaxo

Wellcome plc and SmithKline Beecham plc, both English public
limited companies, by way of a scheme of arrangement for the
merger of the two companies.

 GSK and its subsidiary and associated undertakings

constitute a major global healthcare group engaged in
the creation, discovery, development, manufacture and
marketing of pharmaceutical and consumer healthrelated products.
GSK has its corporate head office in London and has its
US headquarters in Research Triangle Park, North
Carolina, with operations in some 120 countries, and
products sold in over
150 countries.

 1st pharmaceutical company to sign up to the All Trials

campaign for research transparency.
Invested 3.4 billion in 2013 in our search to develop new
medicines, vaccines and consumer products.
Six major new products approved in 2013 (in areas
including respiratory disease, HIV and cancer).
86 manufacturing sites in 36 countries making our
medicines, vaccines and consumer healthcare products.
860 million vaccine doses were distributed to 170
countries in 2013, 80% of which were to developing
countries.
Employed more than 99,000 people in over 100
countries, with more than a third of these in emerging
markets.

Chairman:
Sir Christopher Gent

Chief Executive Officer:

Andrew Witty

 Whether this is through an innovative manufacturing

partnership, or through a charity partnership to save the
lives of children around the world, GSK is committed to
striking up collaborations that allows to devise new,
imaginative ways of working.
GSK currently have three large corporate partnerships
that are dedicated to helping us improve our business
and enhancing the health and well-being of people
around the world.

 GSK and the McLaren Group are working together to

help drive innovation and winning performance across
our business.
Through unique partnership, GSK is identifying
opportunities to align the high-tech approach applied by
the McLaren Group.

 Despite strong economic growth in many parts of Africa

over the last few decades, access to affordable
healthcare is still one of the greatest challenges to
sustained economic development.
GSK have formed a partnership with Barclays that aims
to increase access to affordable healthcare and
medicines for people living in Zambia, while promoting
economic development. Both Barclays and GSK have a
long history offering services across Africa.

 In 2013 GSK embarked on an ambitious global

partnership with Save the Children to share expertise and
resources and focus on following three areas in order to
make a lasting change for the worlds most vulnerable
children.
More healthcare workers in these regions
Vaccines and medicines
Simple nutritious food

GSK MISSION

Do more
Feel better
Love longer

 Grow a diversified global business We are

diversifying our business to create a more balanced
product portfolio and move away from a reliance on
traditional white pill/western markets. We are investing in
key growth areas such as Emerging Markets, Japan,
Vaccines and our Consumer Healthcare business.

 Deliver more products of value We aim to sustain

an
industry-leading pipeline of products, ensuring that they
demonstrate value for healthcare providers. Our R&D
strategy is built around focusing on the best science,
diversifying through externalisation of research, and
improving the returns on investment.

 Simplify the operating model GSK is a large and

complex organisation. We are transforming our
operating model to reduce complexities, improve
efficiency and reduce costs

 Sales in the world pharmaceutical market rose slightly to

511 billion (CER) in the year to September 2013, from
499 billion in the previous year, according to the industry
information company IMS.
Emerging markets and Asia Pacific saw the largest sales
growth at 10%, pushing the proportion of total sales from
this region up to 22% for 2013.
The IMS Institute for Healthcare Informatics predicts that
annual spend on prescription medicines will grow slowly
between 1-4% in North America, Europe and Japan,
whereas spending in emerging nations will grow 10-13%
overall as a result of economic expansion and population
changes in these markets.

Consumer Healthcare Products Category

Colgate-Palmolive
Johnson & Johnson
Procter & Gamble
Reckitt Benckiser
Unilever
Pfizer
Novartis.

Competitors

AbbVie

Amgen, AstraZeneca
Bayer

Bristol-Myers Squibb

Eli Lilly
Johnson & Johnson
Merck & Co

In addition, many other locally-operating companies compete with GSK in certain markets.

Novartis
NovoNordisk
Pfizer
Roche Holdings
Sanofi
Takeda

 R&D is considered foundation of the organization

3.4bn
Core R&D expenditure in 2013
In 2013 GSK spent 3.9 billion in total, in our search to
develop innovative medicines, vaccines and consumer
products.

Pharmaceuticals

2,726

80

Vaccines

496

15

Consumer Healthcare

178

 global commercial presence in more than 150 markets

a network of 86 manufacturing sites in 36 countries
large R&D centres in the UK, USA, Spain, Belgium and
China.

business is structured as a
combination of regional units and
areas of focus.
For Pharmaceuticals and Vaccines,
we operate in geographical
segments that combine these two
businesses.
Our Consumer Healthcare business
functions as a global unit, as does
ViiV Healthcare, the specialist HIV
company we founded with Pfizer in
2009, joined by Shionogi in 2012.

 Grow a diversified global business

Deliver products of value
Simplify the operating model

 Revived R&D in 2007

R&D is no longer a budget for GSK. R&D is an
opportunity to invest and find new medicines.
50% of discovery done internally and about 50% done
outside the company.

 Neuroscience is challenging
This 1.5kg organ is very difficult to understand
GKS sees neurology as an area with tremendous
potential
Refocus neurosciences research on areas where there is
greater evidence of the causes, characteristics and
mechanisms of disease.

 Supporting greater access to vaccines is at the heart of

companys business.
Aimed to improve access to immunization no matter
where in the world people live.

 Making radical changes to work with doctors and other

healthcare professionals.
New practices are intended to provide doctors with high
quality up-to-date information about medicines to help
them make the best treatment choices for their patients.